<SEC-DOCUMENT>0001104659-21-091165.txt : 20210712
<SEC-HEADER>0001104659-21-091165.hdr.sgml : 20210712
<ACCEPTANCE-DATETIME>20210712160809
ACCESSION NUMBER:		0001104659-21-091165
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210712
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210712
DATE AS OF CHANGE:		20210712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36598
		FILM NUMBER:		211085631

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		(608) 441-8120

	MAIL ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2122017d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT>Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>July 12, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CELLECTAR
BIOSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT>(<I>Exact name of registrant as specified in its charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; width: 32%; font-size: 10pt; font-weight: bold">Delaware</TD><TD STYLE="text-align: center; width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 32%; font-size: 10pt; font-weight: bold">1-36598</TD><TD STYLE="text-align: center; width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 32%; font-size: 10pt; font-weight: bold">04-3321804</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: center">(State or other jurisdiction <BR>
of incorporation)</TD><TD STYLE="text-align: center; font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: center">(Commission <BR>
File Number)</TD><TD STYLE="text-align: center; font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: center">(I.R.S. Employer<BR>
 Identification No.)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>100
Campus Drive, Florham Park, New Jersey 07932</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT>(<I>Address of principal executive offices, and zip code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(608)
441-8120</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT>(<I>Registrant's telephone number, including area code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 34%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.00001</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLRB</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ Capital Market</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM 7.01&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGULATION FD
DISCLOSURE</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On July 12,
2021, we </FONT>issued a press release announcing that we have entered into a development and commercialization collaboration with LegoChemBio,
a clinical stage South Korea-based biotechnology company, for the development and commercialization of novel first-in-class phospholipid
drug conjugates (PDCs). A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM 9.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL STATEMENTS AND EXHIBITS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 82%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="tm2122017d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><A HREF="tm2122017d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release dated July 12, 2021, titled &ldquo;Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs)&rdquo;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Dated: July 12, 2021</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CELLECTAR BIOSCIENCES, INC.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left">/s/ Dov Elefant</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 42%">Dov Elefant</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Financial Officer</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2122017d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right; text-indent: 0.5in; background-color: white"><IMG SRC="tm2122017d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Cellectar
Announces a Co-Development and Commercialization </B></FONT><B>Collaboration with</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>LegoChemBio for New Small Molecule Phospholipid Drug
Conjugates (PDCs) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>Development of Multiple
Novel PDCs </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FLORHAM
PARK, N.J., July 12, 2021</B></FONT> --&nbsp;Cellectar Biosciences, Inc.&nbsp;(NASDAQ: CLRB), a late-stage clinical biopharmaceutical
company focused on the discovery and development of drugs for the treatment of cancer, today announced that it has entered into a development
and commercialization collaboration with LegoChemBio, a clinical stage South Korea-based biotechnology company, for the development and
commercialization of novel first-in-class phospholipid drug conjugates (PDCs).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Under the agreement,
the two companies have the option to jointly develop three new small molecule PDCs utilizing Cellectar&rsquo;s proprietary drug targeting
platform, phospholipid ether (PLE) technology and LegoChemBio&rsquo;s proprietary drug conjugate linker-toxin platform. The co-development
option is exercisable at defined points with either party allowed to acquire full global commercialization rights. The parties have further
agreed to focus development of the drug candidates on solid tumors with significant unmet medical need and potential for accelerated regulatory
pathways . Details of the financial terms of the agreement have not been disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;</FONT>This
partnership reflects the shared commitment of LegoChemBio and Cellectar to rapidly provide novel targeted therapies to patients with difficult
to treat cancers. LegoChemBio&rsquo;s proprietary and validated ADC linker-toxin platform technology is well-suited to be combined with
our validated PLE tumor targeting technology to generate new PDC&rsquo;s&rdquo; said James Caruso, president and CEO of Cellectar. &ldquo;This
collaboration has potential to further enrich our oncology pipeline and builds upon our strategy of developing our PDC platform across
a multitude of targeted cancer treatment modalities, including radioisotopes small molecules as well as others.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Yong-Zu Kim, CEO of LegoChemBio said, &ldquo;This
collaboration is of great significance for the expansion of the application of LegoChemBio&rsquo;s ADC linker-toxin platform using an
innovative drug delivery platform technology with a novel mechanism beyond antibodies. Through this cooperation with Cellectar and its&rsquo;
validated competitive platform technology in the field of targeted therapies, we will drive our research capabilities to create novel
PDC clinical candidates with full speed.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Cellectar Biosciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Cellectar Biosciences
is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently
and through research and development collaborations. The company&rsquo;s core objective is to leverage its proprietary Phospholipid Drug
Conjugate&trade; (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better
safety as a result of fewer off-target effects. The company&rsquo;s PDC platform possesses the potential for the discovery and development
of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development
collaborations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The company&rsquo;s product
pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and proprietary preclinical
PDC chemotherapeutic programs and multiple partnered PDC assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, please visit</FONT> <U>www.cellectar.com</U> and <U>www.wmclinicaltrial.com</U> or join the conversation by liking and
following us on the company&rsquo;s social media channels: <U>Twitter</U>, <U>LinkedIn</U>, and <U>Facebook</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statement Disclaimer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This news release contains
forward-looking statements. You can identify these statements by our use of words such as &quot;may,&quot; &quot;expect,&quot; &quot;believe,&quot;
 &quot;anticipate,&quot; &quot;intend,&quot; &quot;could,&quot; &quot;estimate,&quot; &quot;continue,&quot; &quot;plans,&quot; or their
negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current
beliefs and expectations as to such future outcomes including our expectations of the impact of the COVID-19 pandemic. Drug discovery
and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of CLR 131, the
ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development
thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability
to maintain orphan drug designation in the United States for CLR 131, the volatile market for priority review vouchers, our pharmaceutical
collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product
pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic
reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2020. These forward-looking
statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Investors:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Monique Kosse</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Managing Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">LifeSci Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">212-915-3820</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>monique@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2122017d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2122017d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !& .@# 2(  A$! Q$!_\0
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M,2?.ZNP$,MWD1$MR."<8\*_;D_;2\6_M[_$NZ_9R_9VNO,AU1);3Q/XKA/\
MHR6OW)PDH!VVRAMKRCF5BJ1Y##S?6]>_:S/_  4^_9QU7P]^SWXWL?"'C*=U
M36K3Q# ]MJ%GIK^9%*8_+$HWL3'B2(N%# %HW92+"_LC>-OV!OV<--\/?LU>
M'/#&O>*M7OD'B76?$$@2YNE$3@3@%T7:CG"Q[B$#'$;L\CU\_"K*%15:71I]
M]CP,>JF*KU<9ECDZ%10E4G"TG)1]U4Z26JZ\[>UWZ/T[]@G]@+P+_P $^/@Y
M'X8\(VJW&I7@CEUS79X@+W7+A00'D/.V-=S>7$#MC#-U9G=O<J^ ?$O["7[9
M?Q\LFTWQG^U#8^"--C8SQR^#=-/VJ1^ $9XH[*14P6/^M;D+\ISD>O?L+_\
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MK26L9I>]?>,DE>[ZOJQ5J<?8*-)/247M;:46W:RZ+HCW>O'OVF/^2T?L\_\
M90+O_P!17Q!6A_PEOQI_Z$#X7_\ A?WW_P IJ=^TA\./%'C+6OAOK?A.WT&^
MU'P)XGDUN2SU?4);""\BDTC4M/*":*"=E<-?*X_=D$1D9&17-1@X5/>:U4EN
MNS7?0Z:T^>'NIZ.+V?=/J>GU\S?\%)M(TG7Y_@;9ZYX!N/BAID_Q&VR^&8;6
MTNFU)O\ A'];*9CNY(K<K&^V5C*ZJ%B)YQ@^D?\ "6_&G_H0/A?_ .%_??\
MRFI/VF/AMXL\::M\-M:\'1>';O4_ GBEM<EM-9OIK*"\@?2M1T]T66*&9E<?
M;@PS&1\AS5X2]&NI2:Z]5V?5/3U(Q5JU%QBGTZ/NNC6IY1X!_9E^%'C#Q;::
M=J'[%.C^%+.XW^9JNJ^&O!TEI:[49AO6UO9YCN("#9$W+#.%RP]A^/?BR+]E
MG]D;QMKWA71](M(OAYX2O]2TG2X[<06$7V.SDEBA$<>T+%^[5=J;<+P,56_X
M2WXT_P#0@?"__P +^^_^4U=5)X7F^*GPHO=#\=Z)I"#Q!97&G:OI=EJ$M]9R
M02AXVC$[10.P>)N?W:$%B!G 8U5K3E.,JVL4UHI7_.3)I4H1C*-'233U<;?^
MVH\T^$'_  3Y^''P]TV2\\1:!I'Q%\;ZHYN=;\6^)M-@O]5U:X8*&.^16\J$
M!56."/$<:*H ZD[WPZ_8U\"?!?XMMXN\#::? [WEG)9ZIHV@B.ST76LLK1SS
MV:IY?VB(AMLT820B5U=G4@# \!^$OC=\"_#-KX9L9?!?Q6TK30T-AK/B37KK
M0=82U!(AANO)LKR.[F1 H:Z!@,AY,0;+-U/PVT?XJZK\0_[<\9ZMX2T704L9
M;:+PGH,4FH SLT!6ZFU.=(7DVA)@L4=K"H$YW-(54BZU2NW*3K73\]_+EW7E
M=)+RT)HTZ*48JE9KRV\^;9^=FVRCXR_83^"7CS5=3U+6O@_\,-4U35Y)+B]O
MKGPM9275U+(27D>4Q;R[$DE\[LG.<UY;_P $]OV-/A _[('P/\5'X4_#8^)S
MX.T'53K!\,V7V\WGV*WE^T^?Y?F>=YGS^9NW;N<YYKZI==Z$>HQ7"_LN_"V]
M^!O[,_P[\%:E/:W6H^#_  QINB74UL6,,TMM:Q0NR%@&VED)&0#@C(%9QQM7
MZNX<[W75[6?_  "Y8.E[=3Y%:SZ+>Z,3]L3XJ:S\.?A(NG>$G"^/O'5]'X7\
M*DQ-(MO?W*OF[<".0&*T@2XO) R[6CM'7.6%>-?"?X!6O_!,WXZ^#=%\&P7#
M_"/XG10:!K;WMU\VC^(;>V*VFI,=PC+ZDL8MIML2;[B.U(;=)L;L?CQ^P#H?
M[8/[0G_"0?%BVM?$7@SPQI:V'A/0(KN:)8;B9A)>W]PT8C?S6V00QQB1T5(F
M;[TN$YKQA_P1@^ ]WX6OU\*^$_\ A#?%0@=]$\06FIZA)<:#?@$VU[&IN0&>
M&4)( 2 2@!/-=V&K86G15"<W[R]ZT;K7;7F3]W?;>^Z./$4<54JNM""O%^[>
M5GIOIRM>]MOM;9E[_@M"T:_\$R?BH9@#$+2S+@KG*_;[;/'?BO';[]HW_@GO
MIEG+<7/@#X?6]O ADDEE^"UZB1J.223IF !ZFOHK]K#]GGQK^U5^P9JWP^U"
M\\,6/COQ!IMC%?7,+SC2ENHIX)9FC)0RB-C&^T%21D YY->[7-M'>6[PS1I+
M%*I1T==RNIX((/!!%11Q=*CAHTI.3?-+X9<NEHZ_"[WL[%UL+5JXAU(J*7+'
MXHWUO+S5MU<^,_V!=.TC7/VO/&GBOX->'+[P?^SWK?A+39%@?P_<:'IGB'76
MD9EU#3;6:*/;$+()%+)&D:ROY9Q)M\RBO:_V3OV;M6_9/&N>#M-U2TU#X513
M?;?"5E/O_M+PWYKN]QIQ?!$]HKG? [-YJ"1HFWJB/17'F5:-6OS0=U9)/JTE
MI?S[_AI8ZLNHRIT>6:L[MM=+M]/+M^.IW/QT^"^@_M%?!WQ)X&\3VWVO0O%.
MGRZ?=J%0O&KK@21EU8+*C;71L':Z*PY K^7C]L?]D;Q;^Q%\?-9\!>,+.6&[
ML',MC>>7M@U>S+,(KN$Y(,;A3QDE&#HV'1@/ZLJ\6_;A_8'^'?\ P4!^&$7A
MKQYI\QDT^1I]+U>Q98M1TB1L!S#(RL-KA5#HRLC;5)7<B,OL\,\0O+:KA4UI
MRW\GW7Z_\ \CB/(5F%-3IZ5([>?D_P!#\[_^"8__  <6:)I'@*Q\%?M!W6J0
MW^EH(+/QE%;27JWD"HV!?)'NF\X%542QI)YF\%PA5I'_ $A\&?MY?!+XA:9#
M=Z-\7/AO?1S0I/L7Q':++&K+N'F1M('C;!Y5U# Y! (K\+OVJO\ @@/^T%^S
MMK.J3:%X<_X67X7LR9+?4_#S+)=31F0H@:Q+?:/-V[698EE1=W$C $CY#\??
M"KQ1\*=<ETSQ1X;U[PWJ5N0LMIJNGRV<\9(! 9)%5AD$'D=Z^MK<,95F,O;X
M.K:_2-FONW7I^!\M2XDS3+X^QQ=.]NKNG]^S]?Q/Z5/CG_P5U_9R_9]TK[1K
M'Q6\+:I<.)1%9>'[D:U<N\:@^6RVOF"(MD!3,44G^+@D?B5_P58_X*T^)?\
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MD5,E)#'^YM5- T&Q\*Z%9:7I=E::;IFFP):VEI:PK#!:PHH5(XT4!515  4
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
